MINERVA NEUROSCIENCES INC (NERV) Stock News

USA - Nasdaq - NASDAQ:NERV - US6033802058 - Common Stock

3.78 USD

+0.01 (+0.27%)

Last: 11/26/2025, 8:00:01 PM

3.76 USD

-0.02 (-0.53%)

After Hours: 11/26/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NERV Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

9 days ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

23 days ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

23 days ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

a year ago - By: BusinessInsider

News Image

NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024

2 years ago - By: InvestorPlace

NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024

a month ago - By: Benzinga - Mentions: PRE KIDS AVR AKBA ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a month ago - By: Benzinga - Mentions: SLP IBIO PRPH ARCT ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: Stocktwits

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

a month ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation

a month ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation

4 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

4 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

7 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

7 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

9 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

9 months ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

a year ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

a year ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

a year ago - By: InvestorPlace

NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024

a year ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

a year ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

2 years ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

2 years ago - By: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates